Tools
Tools
Dabira, Edgard Diniba, Soumare, Harouna M, Lindsay, Steven W, Conteh, Bakary, Ceesay, Fatima, Bradley, John, Kositz, Christian, Broekhuizen, Henk, Kandeh, Balla, Fehr, Alexandra E, Nieto-Sanchez, Claudia, Ribera, Joan Muela, Peeters Grietens, Koen, Smit, Menno 
ORCID: https://orcid.org/0000-0003-3405-6638, Drakeley, Chris, Bousema, Teun, Achan, Jane and D’Alessandro, Umberto
(2020)
'Mass Drug Administration With High-Dose Ivermectin and Dihydroartemisinin-Piperaquine for Malaria Elimination in an Area of Low Transmission With High Coverage of Malaria Control Interventions: Protocol for the MASSIV Cluster Randomized Clinical Trial'. JMIR Research Protocols, Vol 9, Issue 11, e20904.
|
Text
m.smit_jmir.pdf - Published Version Available under License Creative Commons Attribution. Download (151kB) | Preview |
Abstract
Background: With a decline in malaria burden, innovative interventions and tools are required to reduce malaria transmission further. Mass drug administration (MDA) of artemisinin-based combination therapy (ACT) has been identified as a potential tool to further reduce malaria transmission, where coverage of vector control interventions is already high. However, the impact is limited in time. Combining an ACT with an endectocide treatment that is able to reduce vector survival, such as ivermectin (IVM), could increase the impact of MDA and offer a new tool to reduce malaria transmission.
Objective: The study objective is to evaluate the impact of MDA with IVM plus dihydroartemisinin-piperaquine (DP) on malaria transmission in an area with high coverage of malaria control interventions.
Methods: The study is a cluster randomized trial in the Upper River Region of The Gambia and included 32 villages (16 control and 16 intervention). A buffer zone of ~2 km was created around all intervention clusters. MDA with IVM plus DP was implemented in all intervention villages and the buffer zones; control villages received standard malaria interventions according to the Gambian National Malaria Control Program plans.
Results: The MDA campaigns were carried out from August to October 2018 for the first year and from July to September 2019 for the second year. Statistical analysis will commence once the database is completed, cleaned, and locked.
Conclusions: This is the first cluster randomized clinical trial of MDA with IVM plus DP. The results will provide evidence on the impact of MDA with IVM plus DP on malaria transmission.
Trial Registration: ClinicalTrials.gov NCT03576313; https://clinicaltrials.gov/ct2/show/NCT03576313
International Registered Report Identifier (IRRID): DERR1-10.2196/20904
| Item Type: | Article |
|---|---|
| Subjects: | QV Pharmacology > Anti-Inflammatory Agents. Anti-Infective Agents. Antineoplastic Agents > QV 256 Antimalarials WA Public Health > Preventive Medicine > WA 110 Prevention and control of communicable diseases. Transmission of infectious diseases WC Communicable Diseases > Tropical and Parasitic Diseases > WC 750 Malaria WC Communicable Diseases > Tropical and Parasitic Diseases > WC 765 Prevention and control |
| Faculty: Department: | Clinical Sciences & International Health > Clinical Sciences Department |
| Digital Object Identifer (DOI): | https://doi.org/10.2196/20904 |
| Depositing User: | Stacy Murtagh |
| Date Deposited: | 20 Nov 2020 11:06 |
| Last Modified: | 20 Nov 2020 11:06 |
| URI: | https://archive.lstmed.ac.uk/id/eprint/16165 |
Statistics
Actions (login required)
 |
Edit Item |